Cleveland Clinic News Service | 216.444.0141
We’re available to shoot custom interviews & b-roll for media outlets upon request.
CCNS health and medical content is consumer-friendly, professional broadcast quality (available in HD), and available to media outlets each day.
images: 0
video: 0
audio: 0
text: 0
The effects of progressive multiple sclerosis (MS) could one day be significantly reduced for thousands of patients, according to the results of a clinical trial led by a Cleveland Clinic neurologist.
The drug ibudilast, a pill previously used to treat asthma and some neurologic symptoms in Japan, was found to slow the progression of brain atrophy in progressive MS patients by nearly half (48 percent). That compares to a reduction in brain atrophy of 18 percent by the only currently approved treatment for progressive MS, which is a form of chemotherapy.
“These results are very encouraging,” said Dr. Robert Fox, Vice Chairman for Research at the Cleveland Clinic Neurological Institute and the study’s principal investigator. “Our hope is that the benefit of ibudilast in slowing shrinkage of the brain, will also translate to a slowed progression of associated physical disabilities, as well.”
Dr. Fox presented the findings from the study in Paris on October 28, at the MSParis2017 ECTRIMS/ACTRIMS meeting. The two-year trial — which included 255 subjects at 28 trial sites in the U.S. – also confirmed that performing an advanced MRI technique on patients is an effective way to measure the impact of therapies on brain health, which should help researchers further monitor the impact of MS treatments.
About half of MS patients have the progressive form of MS, an autoimmune disease in which the body’s immune system mistakenly attacks normal tissues. Ibudilast, the first non-anti-inflammatory drug to show promise, is also proving to be relatively safe and well tolerated, per the trial’s findings.
While emphasizing that additional and more comprehensive studies of ibudilast are needed before it could be considered for approval for general use, this drug may meet a significant unmet need for people living with MS.
Dr. Fox noted that the drug has received fast-track designation from the U.S. Food & Drug Administration (FDA).
“This paves the way for us to develop therapies for MS faster than we could before.”
Cleveland Clinic is a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education. Located in Cleveland, Ohio, it was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation. Cleveland Clinic has pioneered many medical breakthroughs, including coronary artery bypass surgery and the first face transplant in the United States. Cleveland Clinic is consistently recognized in the U.S. and throughout the world for its expertise and care. Among Cleveland Clinic’s 81,000 employees worldwide are more than 5,743 salaried physicians and researchers, and 20,160 registered nurses and advanced practice providers, representing 140 medical specialties and subspecialties. Cleveland Clinic is a 6,690-bed health system that includes a 173-acre main campus near downtown Cleveland, 23 hospitals, 276 outpatient facilities, including locations in northeast Ohio; Florida; Las Vegas, Nevada; Toronto, Canada; Abu Dhabi, UAE; and London, England. In 2023, there were 13.7 million outpatient encounters, 323,000 hospital admissions and observations, and 301,000 surgeries and procedures throughout Cleveland Clinic’s health system. Patients came for treatment from every state and 132 countries. Visit us at clevelandclinic.org. Follow us at twitter.com/CleClinicNews. News and resources available at newsroom.clevelandclinic.org.
Editor’s Note: Cleveland Clinic News Service is available to provide broadcast-quality interviews and B-roll upon request.
